The condition appears to be triggered when the optic nerve swells, choking off its blood supply because the nerve's pathway ...

EyePoint Pharmaceuticals Inc. (EYPT), which reported positive interim 16-week data from its phase II VERONA clinical trial last ...

At a single academic tertiary referral center, mild intraocular inflammation developed in four eyes following intravitreal ...

today announced that the first patient has been dosed in the OCU200 Phase 1 clinical trial for diabetic macular edema (DME). “OCU200 has the potential to change the treatment landscape for DME ...

Breakthroughs in age-related macular degeneration (AMD) treatments have revolutionized the management of this progressive and potentially devastating eye disease. These include treatments such as ...

DelveInsight's Diabetic Macular Edema Market report offers an in-depth understanding of the epidemiology and market trends in the 7MM. LAS VEGAS, NV, UNITED STATES, January 13, 2025 /EINPresswire ...

The price you pay for Gilenya may depend on factors such as your dosage, whether you have health insurance, and the pharmacy you use. Financial assistance may be available to help you with the ...

The Brooklyn-based startup is specifically targeting people with macular degeneration. The degenerative eye disease affects roughly 13% of U.S. residents aged 40 and up, according to figures from ...

Diabetic macular edema can result in low vision or vision loss. Early treatment can help preserve vision longer. Diabetic macular edema (DME) is a complication of diabetes. Over time, high blood ...

Novartis is planning a filing for its Gilenya multiple sclerosis drug after a late-stage study showed it reduced multiple sclerosis relapses compared with standard care in children. The company's ...